These findings provide a comprehensive characterization of JAK/STAT pathway mutations in H/L EOCRC patients, underscoring the predominance of missense mutations alongside structural alterations that may influence tumor progression and treatment response. This evidence concerns the gene SOAT1 and neoplasm.